Scaffold attachment factor B1 (SAFB1) is an integral component of the nuclear matrix of vertebrate cells. It binds to DNA on scaffold/matrix attachment region elements, as well as to RNA and a multitude of different proteins, affecting basic cellular activities such as transcription, splicing and DNA damage repair. In the present study, we show that enhancer of rudimentary homologue (ERH) is a new molecular partner of SAFB1 and its 70% homologous paralogue, scaffold attachment factor B2 (SAFB2). ERH interacts directly in the nucleus with the C-terminal Arg-Gly-rich region of SAFB1/2 and co-localizes with it in the insoluble nuclear fraction. ERH, a small ubiquitous protein with striking homology among species and a unique structure, has also been implicated in fundamental cellular mechanisms. Our functional analyses suggest that the SAFB/ERH interaction does not affect SAFB1/2 function in transcription (e.g. as oestrogen receptor a co-repressors), although it reverses the inhibition exerted by SAFB1/2 on the splicing kinase SR protein kinase 1 (SRPK1), which also binds on the C-terminus of SAFB1/2. Accordingly, ERH silencing decreases lamin B receptor and SR protein phosphorylation, which are major SRPK1 substrates, further substantiating the role of SAFB1 and SAFB2 in the co-ordination of nuclear function.
Introduction
Scaffold attachment factor-B (SAF-B) was originally identified and purified as a large nuclear protein bound to chromatin on scaffold/matrix attachment region (S/MAR) elements via its N-terminal SAF domain [1] . It was subsequently termed SAFB1 because it was found to be a member of a subfamily of three evolutionary related SAF-B proteins, comprising SAFB1, SAFB2 and the more distantly related SLTM. Figure 1A shows the close evolutionary relatives SAFB1 and 2 (70% homology at the amino acid level) and depicts their structural and functional domains: SAFB proteins contain the S/MAR DNA binding SAF box at their N-terminal region, an extended region of extremely high identity at both the amino acid and nucleotide levels (where sumoylation occurs) [2] , a RNA recognition motif domain that has recently been shown to bind preferentially to exons, lncRNA and 3 0 and 5 0 UTRs [3] [4] [5] , nuclear localization signal (NLS)
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and, finally, towards the C-terminal region, a RE-rich and a RG-rich domain. The C-terminal part is of high importance for the functions of SAFB because multiple protein-protein interactions take place in this region, resulting in many of its properties.
One of the best described functions of SAFB is its binding to the oestrogen receptor a (ERa) and repression of its transcriptional activity [6] .This co-repressor activity, residing broadly in the C-terminal domain, extends to several other members of the nuclear Saccharomyces cerevisiae strain pJ69-4A was co-transformed with the plasmids described in (A) in addition to SAFB2-ERH 1 : pGBT9-SAFB2C (549-953) and pVP16-ERH(1-100) and SAFB2-ERH 2 : pGBT9-SAFB2C and pVP16-ERH(1-104). The strains were streaked in the same order on plates containing SCTrp receptor family [7] . The mechanism of repression could implicate other co-repressors; however, this has not been clarified [8, 9] . Elegant studies on SAFB1/2-ERa mobility in the nucleus propose that co-repression is the result of reduced intra-nuclear mobility of the ERa because of its indirect tethering to the nuclear matrix via SAFB1/2 under ligand binding [10] . As an androgen receptor (AR) co-repressor, SAFB1 appears to repress AR activity by associating with members of the polycomb repressive complex 2 at AR-interacting chromatin sites [11] . SAFB1 was also found to associate and co-localize with p53 in the nuclear matrix under genotoxic stress, resulting in the repression of p53 transcriptional activity [12] . These associations are also mediated by the C-terminal region of SAFB1. The implication of SAFB1 in transcription has been reported in several cases, where it has been shown to affect the transcription of multiple genes, mostly negatively [6, 7, 11] . A small motif in the RG-rich region also appears to implicate SAFB1 in DNA damage response because it is necessary and sufficient for its poly(ADP-ribose) polymerase 1-and poly(ADP-ribose)-dependent accumulation at damaged chromatin, which further signals DNA damage to the cell in a very fine tuned manner [13] .
Relatively soon after its discovery, SAFB was proposed to be a tumor suppressor in breast cancer, based on observations including a loss of heterozygosity of the SAFB1/2 locus not only in sporadic breast cancer patients [14, 15] , but also in other types of cancer [15, 16] . Immunoblotting of primary human breast tumors revealed widely varying levels of SAFB1 expression, with some tumors even lacking any detectable SAFB1 protein [17, 18] . Loss of SAFB1 or very low expression resulted in a more aggressive tumor phenotype, which led to a worse overall patient survival. However, there was no correlation between SAFB1 levels and outcome in tamoxifen-treated patients, suggesting the SAFB1 association with worse patient outcome was not ER related but, instead, was a result of other SAFB functions [18] .
Very early, SAF-B was shown to play a role in splicing and, most importantly, in the transcription-splicing co-ordination. One of the first studies describing SAFB1 in 1998 proposed that, because it can form a ternary complex with S/MAR DNA and SR proteins and also bind to RNA polymerase II, it might be responsible for tethering transcription-splicing hubs to the nuclear matrix. In the same study, SAFB was shown to influence splice site selection in vivo when overexpressed and it was proposed to couple transcription and splicing through its S/MAR binding properties [19] . Subsequently, many studies, including our own, have supported an implication of SAFB1 in splicing regulation and, most particularly, transcription-RNA maturation coordination: it has been shown to interact with the SR splicing factor SRrp86 [20] and with chromodomain-helicase-DNA-binding protein 1, a protein involved in DNA remodeling and splicing [21] . Biochemical and localization studies in HeLa cells led to the identification of transient and more labile (in many cases RNA-dependent) SAFB-protein complexes containing Sam68 and T-STAR, proposed to play a role in alternative splicing [22] . Our work has shown that SAFB1 and SAFB2 interact in the nucleus with the major SR protein modulator kinase, SR protein kinase 1 (SRPK1) [23, 24] . This interaction represses the activity of the kinase, further implicating SAFB proteins in splicing co-ordination [25] . Recently, additional studies have proposed that SAFB1 is an important molecule either for the orchestration of transcription initiation and the RNA processing of specific genes [26] or for the isoform-specific expression of coding and noncoding genes through its RNA binding properties, which are just recently starting to be explored [4] .
In the present study, we have identified a novel interaction of SAFB1 and SAFB2 in mammalian cells with another ubiquitous and multifunctional protein, enhancer of rudimentary homologue (ERH). This interaction takes place at the nuclear matrix, where a portion of the nuclear ERH is shown to reside together with SAFB1/2. The interaction does not appear to affect the ERa co-repressor activity of SAFB1/2, although it does alleviate the inhibition that the SAFB1/2 proteins exert on SRPK1. We show that changes of ERH levels in vivo affect the association of SRPK1 with the SAFB proteins at the nuclear matrix, resulting in an altered phosphorylation of its major substrates, lamin B receptor (LBR) and SR splicing factors.
Results

SAFB1 interacts with ERH in a yeast two-hybrid system
The interaction of the nuclear factor SAFB with SRPK1 results in the in vitro and in vivo repression of the activity of the kinase. In our quest to understand the biological significance of such an interaction, we used the C-terminal part of SAFB1 as bait in a twohybrid system assay, aiming to detect new interacting proteins with SAFB1. In the initial assay, 550-931 amino acids of rat SAFB1 were used as bait versus a mouse cDNA library [27] . Among the various isolated clones, we selected for those that displayed a strong interaction with SAFB1 in the yeast two-hybrid assay. From the 100 clones that were selected and categorized according to the strength of the interaction, 26 were verified for their plasmid-dependent phenotype and their plasmids were sequenced. Eleven were found to correspond to SAFB1, three to SAFB2 and one to SLTM (all including the RE-rich region), confirming the SAFB homo-and heterodimerization properties of the SAFB family members (data not shown). From the remaining 11 strongly interacting clones, we chose to study ERH (two independent clones). The growth of yeast SAFB1-ERH co-transformants on 50 mM [3-amino-1, 2,4-triazole (AT)] plates is shown in Fig. 1B . We also examined the interaction of SAFB2 with ERH by creating a bait of the respective C-terminal region of human SAFB2 (549-953 amino acids). As indicated by the phenotype displayed by SAFB1-and SAFB2-ERH co-transformants on 5 mM AT or X-Gal plates (Fig. 1C) , reporter genes HIS3 and lacZ are expressed in yeast, indicating that both SAFB1 and SAFB2 interact with ERH in Saccharomyces cerevisiae cells.
SAFB proteins interact with ERH in mammalian cells
To confirm that ERH interacts with the SAFB proteins in mammalian cells, green fluorescent protein (GFP)-SAFB1 and GFP-SAFB2 chimeric proteins were used. MCF-7 cells were transfected with either GFP, GFP-SAFB1 or GFP-SAFB2 expressing plasmids, and then immunoprecipitation was performed from whole cell extracts with an anti-GFP antibody and the presence of ERH was examined in the precipitates with an anti-ERH antibody. The presence of the relevant SAFB proteins in the extracts was confirmed by the use of specific anti-SAFB1 or anti-SAFB2 antibodies.
First, the specificity of the anti-SAFB1 and anti-SAFB2 antibodies was confirmed by transfecting HEK293T cells (this cell line exhibits higher transfection efficiency) with either GFP-SAFB1 or GFP-SAFB2 expressing plasmids and by immunoblotting the corresponding lysates with the two specific antibodies. Figure 2A distinguishes the endogenous from the exogenously expressed proteins and only the relevant SAFB isoform is revealed by each one of the specific antibodies.
As shown in Fig. 2B , ERH is detected in the precipitate of both GFP-SAFB1 and GFP-SAFB2 expressing MCF-7 cells, whereas it is absent from the GFP expressing or the mock-transfected cells.
We further aimed to detect the endogenous SAF-B-ERH complexes and, accordingly, we immunoprecipitated either SAFB1 or SAFB2 with the specific anti-SAFB1 and anti-SAFB2 antibodies from MCF-7 Cell lysates from HEK293T cells transfected with plasmids encoding GFP-SAFB1 and GFP-SAFB2 were analyzed by western blotting using anti-SAFB1 and anti-SAFB2specific antibodies as indicated. The white arrow marks the position of exogenous SAFB1 or SAFB2 and the black arrow indicates endogenous SAFB1 or SAFB2, respectively. (B) MCF-7cells expressing GFP, GFP-SAFB1 and GFP-SAFB2 were lysed and their extracts were subjected to immunoprecipitation with an anti-GFP antibody. Total cell extracts (input, 1/30 of total quantity; lanes 1-4) and precipitated proteins (IP; lanes 5-8) were analyzed by western blotting using anti-SAFB1, anti-SAFB2, anti-GFP and anti-ERH antibodies, as indicated. The white arrow marks the position of exogenous SAFB1 or SAFB2 and the black arrow indicates endogenous SAFB1 or SAFB2, respectively. (C) MCF-7 cells were lysed and their lysates were subjected to immunoprecipitation with anti-SAFB1, anti-SAFB2 or a control rabbit IgG antibody, as indicated. Total cell extracts (input, 1/30 of total quantity; lane1) and precipitated proteins (IP; lanes 2-4) were analyzed by western blotting using anti-SAFB1, anti-SAFB2 and anti-ERH antibodies as indicated. Only the relevant parts of the blots are shown. Numbers on the left indicate the position of the corresponding molecular weight markers. One representative experiment of three independent experiments is shown. total cell extracts. As shown in Fig. 2C , ERH is detected in both precipitates, confirming that ERH is found in complex with both SAFB1 and SAFB2 in MCF-7 cells. The smaller number of ERH molecules that we detect on SAFB1 compared to SAFB2 could be a result of differential affinity displayed between the two specific antibodies, as well as different epitopes recognized on the SAFB molecules (i.e. the SAFB1 antibody binds to the C-terminal part of the molecule and could partially interfere with ERH binding). The same experiment was performed in HeLa cells, also confirming the existence of the SAFB1/2-ERH complex in these cells (data not shown).
ERH-SAFB interaction is direct
To exclude the involvement of a third protein intervening in the SAFB-ERH interaction in the above assays, we performed pull-down assays with bacterially expressed SAFB and ERH proteins. The R/E-R/G-rich C-terminal domains of SAFB1 and SAFB2 (623-915 and 641-953 amino acids, respectively), as well as the R/G-rich domain of SAFB1 (710-915 amino acids; Fig. 1A ), were expressed in fusion with glutathione S-transferase (GST), and full-length ERH was expressed in fusion with six His residues. As shown in Fig. 3 , His-ERH was specifically retained on GST-SAFB immobilized fusion proteins but not on GST ( Fig. 3A) and, in contrast, GST-SAFB proteins (but not GST) were retained by immobilized His-ERH (Fig. 3B) . Interestingly, His-ERH appears to be strongly retained on the most C-terminal part of SAFB1 (Fig. 3A, lane 8) , which is also confirmed by the inverse experiment (compare lanes 3B, 6 and 8).
The above experiments (Figs 2 and 3) show a direct interaction between SAFB1/2 and ERH in MCF7 cells. Furthermore, their interaction is mapped to the C-terminal RG-rich region of SAFB.
ERH co-localizes with SAFB1/2 in the insoluble nuclear fraction
We further aimed to determine in which particular region of the cell the SAFB/ERH complexes are found. We thus examined the localization of the SAFB proteins and ERH by immunofluorescence in MCF-7 and HeLa cells using anti-SAFB1, anti-SAFB2 and anti-ERH antibodies (Fig. 4A ). As expected, SAFB1/2 shows exclusive nuclear staining, whereas ERH exhibits not only mainly nuclear, but also some cytoplasmic staining. The merged images reveal the colocalization of the two proteins in specific structures inside the nucleus. Co-localization is also revealed when the interacting proteins are exogenously expressed in MCF-7 cells (Fig. 4B ). Furthermore, visual (i.e. scatterplots) and quantitative (i.e. graphs) assessment of microscopy data (Fig. 5) shows that SAFB1/2 co-localize nonrandomly with ERH (as indicated by Pearson's co-efficient) and this involves a substantial fraction (50-70%) of nuclear SAFB-ERH population (as indicated by Manders' co-efficient values).
To further corroborate this result, because these structures might represent the insoluble nuclear matrix where SAFB proteins have been found to reside in their major part [25] , we performed cellular fractionation experiments (shown schematically in Fig. 4C ). Our results show that, indeed, SAFB and ERH proteins are mainly co-localized in the insoluble nuclear fraction, together with lamin B and the core histone 3 (Fig. 4D) , and the cytoplasmic localization of ERH is also evident. Interestingly, all nuclear ERH is found in the insoluble fraction where it appears to reside in complex with SAFB1 and SAFB2 (Fig. 2B) . Note that SRPK1 co-localizes with SAFB1/2, as reported previously [25] , in this fraction, whereas it retains its known cytoplasmic/nuclear distribution.
ERH does not affect the ERa co-repressor activity of SAFB1/2
Our in vitro experiments have mapped ERH binding at the C-terminal RG-rich region of SAFB. As already mentioned, the C-terminal region of SAFB1/2 is responsible for its ERa co-repressor activity. We thus examined the effect of ERH on the activity of SAFB1 and SAFB2 as ERa co-repressors. For these assays, we used MCF-7 cells that express the endogenous ERa. We first examined the dose-dependent repressive activity of SAFB1 and SAFB2 on ERa, using an estrogen responsive element (ERE) driven luciferase reporter to measure ERa transcription activity. As shown in Fig. 6A , both SAFB1 and SAFB2 repress ERa activity in a dose-dependent manner and the quantity required for maximal repression is comparable for the two proteins. We next co-transfected MCF-7 cells with the Flag-ERH expressing plasmid, together with each one of the two co-repressor expressing plasmids, GFP-SAFB1 and GFP-SAFB2. Cell extracts were subsequently either measured for luciferase activity (Fig. 6A , left) or electrophoresed and immunoblotted with different antibodies (Fig. 6A , right). As shown in Fig. 6B , ERH does not affect ERa activity on its own (Fig. 6B, left) or GFP-SAFB1/2 levels, nor is it affected by oestradiol (Fig. 6B, right) . Finally, the presence of exogenous ERH, at equal levels under all conditions tested, does not affect the repressive function of either SAFB protein on ERa transcriptional activity (Fig. 6B) .
ERH inverses the inhibition exerted by SAFB1/2 on SRPK1 activity
Our previous studies have shown that SAFB1/2 interacts and represses SRPK1 activity in vitro. Because both SRPK1 and ERH interact with the C-terminal part of SAFB1/2, we examined the effect of ERH on the repressive activity of SAFB1/2 on SRPK1. We therefore performed in vitro kinase assays with the well-established RS containing N-terminal domain of LBR, as a substrate for SRPK1 [23, 25] . In the presence of SAFB1 or SAFB2, SRPK1 activity was repressed to~30%, as reported previously [25] . As shown in Fig. 7B ,C, (compare lanes 1 and 2) in the presence of the SAFB1 or SAFB2 C-terminal domains, LBR is under-phosphorylated. The addition of increasing quantities of His-ERH on its own did not affect SRPK1 activity (Fig. 7A) , whereas, when ERH was added in a dose-dependent manner in the presence of SAFB1/2, it abolished the repression exerted by SAFB1/2 on SRPK1 activity and re-established LBR phosphorylation to~75% (Fig. 7B,C) . Because ERH appears to de-repress SRPK1 activity by SAFB in vitro, we investigated whether such an effect takes place in vivo. Accordingly, ERH was silenced in HeLa cells by specific siRNA and the phosphorylation levels of LBR were monitored in vivo on LBR immunoprecipitates by the use of an antiphospho-serine antibody. As shown in Fig. 7D , total LBR levels do not change upon ERH silencing, whereas phospho-LBR levels decrease when ERH levels drop, supporting our hypothesis that more SRPK1 molecules are inactive under these conditions.
ERH levels affect SAFB/SRPK association and SR protein phosphorylation in vivo
We next confirmed that the effect demonstrated on LBR would be evident on other known substrates of SRPK1, such as the SR splicing factors. Using the mab104 antibody, which reacts with a conserved phosphorylated epitope on SR proteins [28, 29] , we show that ERH silencing does not affect SRPK1 and SAFB presence or absence of ERH, and under ERH overexpression. As shown in Fig. 8B ,C, when ERH is silenced, more SRPK1 is bound on SAFB and, in contrast, when ERH is over-expressed, less SRPK1 molecules are bound on SAFB (note that total levels of SRPK1-or SAFB-do not change), implying that the change of phosphorylation levels of the SR proteins detected in Fig. 8A is a result of the sequestration of the SRPK1 molecules on SAFB and its subsequent inactivation. This is also demonstrated by our fractionation experiment, where it is evident that, when ERH is silenced, SRPK1 molecules migrate from the nuclear soluble (NS) to the nuclear insoluble (NI) material where SAFB resides (Fig. 8D) .
Discussion
In the present study, we have identified a novel interaction between the nuclear proteins ERH and SAFB1 and 2.
Enhancer of rudimentary homologue is a small and very interesting protein, highly conserved throughout metazoans and plants with a striking homology between species. Human ERH is 100% identical to Xenopus ERH and 76% identical to Arabidopsis thaliana ERH [30] [31] [32] . Intriguingly, its 3D structure is unique, consisting of a four-stranded antiparallel b-sheet packed adjacent to three amphipathic a-helices forming homodimers in solution via the b-sheets [33] . It does not appear to contain a NLS, and it is localized in both the cytoplasm and the nucleus and excluded from the nucleolus [34, 35] . Subsequent to its discovery in Drosophila melanogaster as a mutation enhancing a phenotype resulting from mutations in pyrimidine biosynthesis genes [36] , ERH has been implicated in almost all fundamental nuclear functions: it has been shown initially to play a role not only in transcription [31, 34, 37, 38] , but also in splicing, cell cycle and DNA damage repair (DDR), with this role becoming more prevalent: ERH was shown to interact with the spliceosome protein small nuclear ribonucleoprotein Sm D3 and affect the splicing of the mitotic motor protein centromere-associated protein E, resulting in its involvement in chromosome segregation [32] . The same team has shown that ERH depletion affects the splicing of a small number of genes, mostly involved in cell cycle and DNA replication/repair pathways and further determined specific genes of the DDR pathway affected by ERH [32, 39] . The role of ERH in the regulation of genome integrity via splicing control has been supported by the findings of another study that used a RNAi screen and found that ERH depletion affects the splicing of several genes enriched in DDR [40] . The results that we report establish the ERH-SAFB interaction as direct, taking place in at least two different human cell lines, in the nucleus and most particularly at the nuclear matrix, and suggest specific roles for ERH and SAFB in nuclear function co-ordination through SRPK1 regulation.
Enhancer of rudimentary homologue was one of the preys that showed a strong interaction in a yeast twohybrid screen where the C-terminal 431 amino acids of rat SAFB1 were used as bait versus a mouse embryonic cDNA library. Immunoprecipitation experiments in human cell lines demonstrate the presence of ERH and SAFB in the same complexes. Specific antibodies for SAFB1 and SAFB2 confirm that each one of the two proteins co-immunoprecipitates with ERH. By pull-down experiments, we have shown that ERH binds to both SAFB1 and SAFB2 directly and that the interaction takes place at the last 200 amino acid region of SAFB1, rich in Gly and Arg residues. This region of SAFB1/2 was previously predicted to be intrinsically disordered [41] (and also in our search with different bioinformatics programs such as Dis-EMBL, Globplot, PONDR, PSIPRED), suggesting that it might have the capacity to acquire a different structure upon binding with different molecular partners ('concerted folding and binding') [42] .
We know from previous work that the ERa corepressor activity of SAFB1 and SAFB2 resides at their C-terminal region, where also part of their binding to ERa takes place [6] . We thus assayed SAFB corepression activity in the presence of ERH and did not detect any effect of ERH on the specific SAFB1/2 function. This result could be explained by the fact that ERa appears to have two binding sites on SAFB, a stronger on its central region and a weaker on the C-terminal region, with the latter not well demarcated [6] . It is suggested in the same study that part of the repressor activity of SAFB1 may result from binding of the last 200 amino acids of SAFB1 with the general transcription factor TAFII68. ERH does not appear to compete for TAFII68 binding in this region, if TAFII68 is indeed responsible for SAFB ER a co-repressor activity.
The same last C-terminal part of SAFB1 and SAFB2 binds the kinase SRPK1, resulting in the inhibition of SRPK1 activity [25] . We likewise assayed SAFB1/2 inhibitory activity on SRPK1 catalysis in the presence of ERH. We were able to demonstrate that ERH, which does not affect LBR phosphorylation by SRPK1 on its own, is able to reverse the repressive function of both SAFB1 and SAFB2 on SRPK1 in vitro, in a dose-dependent manner. It is interesting to note that the ERH concentration-dependent recovery of SRPK1 activity appears to be sigmoidal in both cases, which supports the prediction that ERH homodimerizes in solution (33) , which has not yet been demonstrated in vivo. This result suggests that ERH and SRPK1 bind at the same or closely situated subregions of the RG-rich region of SAFB1/2 and also that this binding is inter-exclusive. We further substantiated this result in vivo by silencing ERH and demonstrating that, although neither SRPK1, nor SAFB levels are affected, LBR phosphorylation levels drop, as would be expected from our in vitro results.
We have further shown that the major substrates of SRPK1 (i.e. the SR splicing factors) are also underphosphorylated when ERH is silenced. It would be informative to further determine if and what other substrates are affected under these conditions and to define the domains, structures and motifs of the three molecules involved in these interactions.
We have finally demonstrated that, indeed, SAFB/ SRPK1 association increases when ERH levels drop and, in contrast, when ERH is over-expressed, less SRPK1 is bound on SAFB.
Our immunofluorecsence experiments have detected ERH in a punctuate pattern in the nucleus, excluded from nucleoli and also in the cytoplasm, as already reported [35, 43] , in both of the cell types examined (MCF7, HeLa). SAFB1 and SAFB2 always show speckled nuclear localization excluded from nucleoli in all cell lines examined. ERH shows nonrandom colocalization with both SAFB1 and SAFB2 in discreet nuclear speckles at significant levels, as demonstrated by immunofluorescence microscopy and subsequent evaluation of the collected images. These observations are supported by cellular fractionation experiments revealing that nuclear ERH indeed resides in the NI material where SAFB1 and SAFB2 are also found, as well as the~10% of cellular SRPK1, as described previously [25] . It is interesting that we do not detect any soluble ERH in the nucleus, which suggests that all nuclear ERH is bound in structures remaining insoluble under our fractionation conditions. This is also observed for SAFB1/2, which is not unexpected because the SAFB proteins are known to bind DNA and reside at the nuclear matrix in their major part, independent of the methodological approach used [25, 41, 44] . It is feasible, therefore, that ERH might replace SAFB-bound SRPK1 under certain conditions, as suggested by our experiments. The liberated SRPK1 molecules would thus be catalytically active. This is demonstrated by our fractionation experiment showing that, under ERH depletion, SRPK1 molecules move from the soluble to the insoluble nuclear material and bind on SAFB molecules, as shown by our immunoprecipitation experiments.
SR protein kinase 1 has been shown to move into the nucleus in a cell cycle regulated manner [24, 45, 46 ] not only at the G2/M phase, but also under other signals such as osmotic changes [47] or growth factor signalling [48, 49] , as proposed to account for the implication of SRPK1 in tumor development. Many studies find that SRPK1 levels are mostly elevated in different types of tumors [49] [50] [51] and correlate with cancer progression and worse patient outcome [52, 53] , highlighting SRPK1 as a target for anticancer treatment [54] [55] [56] [57] . Upon entrance into the nucleus, SRPK1 is found not only in nuclear speckles, which are accepted to be storage sites for splicing factors, but also in the nucleoplasm. This movement must be not only timely, but also locally regulated. We have previously proposed that SRPK binding on SAFB-containing complexes might be a way of regulating SRPK activity concomitantly with engaging phosphatases for de-phosphorylation of the splicing factors [24, 25] . Our present results corroborate this hypothesis because ERH silencing clearly affects SR protein phosphorylation without affecting SRPK1 levels. Additionally, SRPK1 has been shown to be part of a the phosphorylation network that governs the localization and movement of LBR at (and into) the inner nuclear membrane [58] . Because phosphorylation of the nucleoplasmic tail of the LBR by SRPK1 [29, 59] regulates its binding to chromatin [60] , SRPK1 might be implicated in nuclear envelope modeling and chromatin architecture.
On the other hand, SAFB is a protein that also exhibits sub-nuclear mobility. Heat shock or cadmium sulfate treatment re-locates SAFB to perichromatin granules [61, 62] , structures with an ambiguous composition and function that were recently demonstrated to contain both RNA and DNA [63] . Structures such as these perform functions that represent the staging of the processing of transcribed RNAs. Perichromatin granules are considered to be intermediate sites for the RNAs being stored prior to export from the nucleus. Splicing factors involved in RNA export found in these particles should thus be hypophosphorylated and the presence of SAFB in these structures might be important with regard to keeping SRPK1 inactive.
Our fractionation experiments did not detect any soluble ERH in the nucleus, suggesting that ERH should be tethered to compact structures throughout the nucleus. To date, there is no information available about ERH sub-cellular trafficking; however, such movements might take place under conditions that still need to be addressed. A very elegant study has used ERH mutants to make structure-function correlations. It was also shown that nuclear ERH localization is punctuate in the nucleus and residues were identified that are required for ERH recruitment either to nuclear speckles or replication foci, as a result of its binding to specific partners on these structures [35] . SAFB has been shown to be localized in either of these structures under certain conditions [13, 19, 64] and our experiments show that the two proteins interact in the nuclear matrix. It is thus conceivable that ERH-SAFB complexes are formed or dissolved in the nucleus of mammalian cells in a regulated manner, stably or transiently, under stress or other signals according to the needs of a cell, in this way coordinating the phosphorylation of SRPK1 substrates. Not unexpectedly, ERH levels have also been found elevated in different types of cancer [32, 65, 66] .
At this stage, we are unable to predict under which exact circumstances each protein complex is formed in human cells. Our work reveals a novel interaction between SAFB and ERH in human cells and further validates the involvement of ERH and the SAFB1/2 proteins in nuclear architecture and the co-ordination of function.
Materials and methods
Plasmids
The following plasmids have been described previously: pGEX-2TK-SAFB1C, pGEX-2TK-SAFB1CDRE, pGEX-2TK-SAFB2C, pGEX-2T-SRPK1, pGEX-2T-NtLBR, pGFP3-SAFB1, pGFP3-SAFB2 [25] and pGBT9-SRPK1aNt [23] . 6xHIS-ERH was kindly provided by R. B. Rose (Department of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, USA). 3xERE-TATA-Luc was kindly provided by P. Moutsatsou (Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece). pCI-Renilla luciferase plasmid was kindly provided by M. U. Muckenthaler (University of Heidelberg, Heidelberg, Germany). To construct pGBT9-SAFB2C, the cDNA fragment coding for amino acids 549-953 of human SAFB2 was amplified by PCR from plasmid pEGFP3-SAFB2, using as primers: sense 5 0 -TTGAATTCGAGCTGAAACCCGGA-3 0 and
containing the underlined EcoRI and BamHI sites respectively. The PCR fragment was digested with EcoRI and BamHI, purified and subcloned into the respective sites of pGBT9 (Clontech, Palo Alto, CA, USA) in-frame with the GAL4 DNA binding domain. To construct rat pGBT9-SAFB1, the cDNA fragment coding for the amino acids 550-931 of rat SAFB1 was amplified by PCR from plasmid rSAF-B-PC [19] , using as primers: sense 5 0 -TTGAATTC-
GATGATGGGAGCACA-3
0 and antisense 5 0 -TTT GGATCCATCACTGGGTCTGCT-3 0 , containing the underlined EcoRI and BamHI sites, respectively. The PCR fragment was digested, purified and subcloned into the respective sites of pGBT9 in-frame with the GAL4 DNA binding domain. Full-length ERH was subcloned into the pFLAG-CMV-2 as a FLAG tag fusion protein at its NH 2 terminus. For this purpose ERH cDNA was amplified by PCR from plasmid pET24b-NHis-ERH, using as primers: sense 5 0 -TT GAATTCGATGTCTCACACCATTTTG-3 0 and antisense 5 0 -TTGGATCCTTATTTCCCAGCCTGTTG-3 0 , containing underlying digested EcoRI and BamHI sites respectively. The PCR fragment was digested with EcoRI and BamHI, purified and subcloned into the respective sites ofpFLAG-CMV-2 in the correct orientation.
Cell culture, transfection and luciferase assay
Human breast cancer cells (MCF-7), human embryonic kidney cells 293 (HEK 293T) and human cervical carcinoma cells (HeLa) were cultured in Dulbecco's modified Eagle's medium (DMEM; Biosera, Nuaille, France) supplemented with 10% FBS (Biosera) and 100 UÁmL À1 penicillin-streptomycin (Biochrom, Berlin, Germany). Cells were routinely grown at 37°C in an incubator with adjusted humidified atmosphere composed of 95% air and 5% CO 2 . Transient transfections were carried out by using poly(ethylenimine; CELLnTEC, Bern, Switzerland) transfection reagent in accordance with the manufacturer's instructions. All of the the oestrogen-dependent assays were based on a previous study [6] . Briefly, MCF-7 cells were pre-incubated for 48 h in phenol red free DMEM (Gibco, 
Subcellular fractionation, SDS/PAGE and western blotting
Subcellular fractionation assays were employed as described previously [35, 36] and as represented schematically in Fig. 4C . Samples were adjusted and loaded for SDS/PAGE electrophoresis to give equivalent cell numbers in each lane. Protein samples were resolved by 16%, 14% or 8% SDS/ PAGE, and analyzed by Coomassie brilliant blue or western blotting using the antibodies: rabbit anti-SAFB1 (dilution 1 : 1000; Bethyl, Montgomery, TX, USA), rabbit anti-SAFB2 (dilution 1 : 2000; Bethyl), rabbit polyclonal anti-GFP serum (dilution 1 : 5000; generously provided by H. Boleti, Hellenic Pasteur Institute, Athens, Greece), goat anti-GST (dilution 1 : 10000; Amersham Biosciences, Piscataway, NJ, USA), rabbit anti-LaminB (dilution 1 : 500; Santa Cruz Biotechology, Santa Cruz, CA, USA), rabbit anti-LBR (dilution 1 : 2500; GeneTex Inc., Irvine, CA, USA), rabbit anti-Histone 3 (dilution 1 : 10.000; Santa Cruz Biotechnology), mouse anti-SRPK1 (dilution 1 : 1000; BD Transduction Laboratories, Lexington, KT, USA), mouse anti-ERH (dilution 1 : 200; Santa Cruz Biotechnology), mouse antiActin (dilution 1 : 5000; Cell Signaling), mouse anti-phospho-Serine (dilution 1 : 1000; BD Transduction Laboratories) and mouse anti-penta His (dilution 1 : 3000; Qiagen, Venlo, The Netherlands). To assess SR protein phosphorylation levels, mab104 mouse monoclonal antibody was used (culture supernatant) [37, 38] . Analysis by immunoblotting was carried out as described previously [39, 40] . Western blotting images were taken using an Uvitec Cambridge Chemiluminescence Imaging System (Uvitec Cambridge, Cambridge, UK) using Alliance software, version 16.06.
Immunoprecipitation
Immunoprecipitation experiments for endogenous or GFP tagged proteins were performed as described previously [41] . Briefly, MCF-7 cell total extracts were incubated for 2 h at 4°C with 1 lg of polyclonal anti-SAFB1, anti-SAFB2, anti-GFP or normal rabbit IgG in buffer 
Protein purification and in vitro kinase assays
Expression and purification of the fusion proteins GST-SAFB1C, GST-SAFB1CDRE, GSTSAFB2C, GST-NtLBR, GST-SRPK1 and His-ERH were performed as described previously [25, 33] . In vitro kinase assays were carried out as described previously [25] . All samples were analyzed by 14% SDS/PAGE followed by Coomassie blue staining and labelled proteins were detected by autoradiography. Relative phosphorylation levels were determined by cutting out both labelled LBR protein bands from gels and measuring their radioactivity by scintillation counting (Wallac 1409; Perkin Elmer, Waltham, MA, USA).
In vitro binding assays
For the GST binding assays, 10 lg of purified GST, GST-SAFB1C, GSTSAFB1CDRE and GST-SAFB2C were immobilized on 25 lL of glutathione-sepharose beads (Macherey-Nagel, D€ uren, Germany) and incubated with 10 lg of purified His-ERH for 3 h at 4°C in 19 PBS, 10 mM EDTA, pH 8 and 0.1 mM PMSF as previously described [67] . The beads were washed three times in the same buffer and bound proteins were eluted with glutathione elution buffer (50 mM Tris/HCl, pH 8.0,10 mM glutathione). Eluted proteins were analyzed by 14% SDS/PAGE and western blotting, using the relevant antibodies. For the reverse experiment, 10 lg of purified His-ERH was immobilized on 25 lL of Ni-NTA beads (Qiagen) and incubated with 10 lg of purified GST, GST-SAFB1C, GST-SAFB1CDRE and GST-SAFB2C for 3 h at 4°C in ice-cold buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole and 0.1 mM PMSF). The beads were washed three times in the same buffer and bound proteins were eluted with 250 mM imidazole, 300 mM NaCl and 1 mM b-mercaptoethanol. Eluted proteins were analyzed after the same analysis.
Immunofluorescence
Immunofluorescence microscopy was carried out as described previously [68] . Briefly, 24 h post transfection, MCF-7 cells grown on coverslips that were fixed with 3% formaldehyde in PBS for 5 min, followed by permeabilization with 1% TritonX-100 at 4°C for 15 min, and then incubated with 1% BSA for 1 h at room temperature. In the case of endogenously expressed proteins, cells were grown on coverslips that were fixed with 4% paraformaldehyde in PBS for 5 min, followed by permeabilization with 0.5% TritonX-100 at room temperature for 5 min, and then incubated with 1% BSA for 1 h at room temperature. Primary antibodies were diluted in blocking solution at the concentrations: anti-SAFB1 1 : 500, anti-SAFB2 1 : 1000, anti-ERH 1 : 50 and anti-FLAG 1 : 1000 (Sigma-Aldrich, St Louis, MO, USA) and incubated overnight at 4°C. Secondary antibodies conjugated with Alexa Fluor 488 and Alexa Fluor 568 were diluted in blocking reagent at the same concentration (1 : 500) and incubated for 1 h at room temperature. Images were taken on a Axioplan fluorescence microscope (Zeiss, Oberkochen, Germany) using an AxioCamMRm CCD sensor and 1009 oil-immersion lens. Collected images were deconvolved using the PSF-based Iterative Deconvolve 3D deconvolution plugin for IMAGEJ (NIH, Bethesda, MD, USA) [69] . To analyze the co-localization between endogenous or exogenous SAFB1 or SAFB2 and ERH, the JaCoP plugin of IMAGEJ was used [70] . Briefly, the nuclear area of individual cells was used as region of interest and JaCoP plugin with Costes' automatic threshold was applied to calculate Pearson's correlation and Manders' colocalization co-efficients.
Yeast two-hybrid method
A yeast two-hybrid screen was performed as described previously [67] . Briefly, for the yeast two-hybrid screening, S. cerevisiae strain pJ69-4A was co-transformed with the rat pGBT9-SAFB1(550-931 amino acids) construct, and an equimolar mixture of embryonic days 9.5 and 10.5 mouse cDNA library, which was constructed in the pVP16 fusion vector [27] . Positive clones were selected on plates containing 5 mM AT (Sigma-Aldrich). For the direct two-hybrid assay, S. cerevisiae strain pJ69-4A was co-transformed with pGBT9-SAFB1C and pVP16-ERH or pGBT9-SAFB2C and pVP16-ERH, and the strains were streaked on synthetic complete medium, as described above.
siRNA-mediated silencing
HeLa cells were incubated in DMEM for 24 h with siRNAs targeting ERH (30 nM; Qiagen) in the presence of Viromer Ò Green Reagent (Lipocalyx GmbH, Halle, Germany). AllStars siRNA (Qiagen) was used as a negative control.
Statistical analysis
Statistical differences between two groups of data were assessed using an unpaired t-test in PRISM, version 5.04 (GraphPad Software Inc., San Diego, CA, USA). P < 0.05 was considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001).
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